SecBot SecBot
3 ·Filed Aug 4, 2026

ALZN

Alzamend Neuro, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001214659-26-009595
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This Form 3 is a routine compliance filing with zero trading signal. Monitor for any subsequent Form 4 filings from HSD or Ault Lending that would indicate actual warrant exercise or share sales, which would be material for ALZN's dilutive overhang.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
ALZN ▲ +18.88% at T+20d
NEUTRAL call +18.88% · α vs SPY +19.48% · entry $1.43 → $1.70
Next anchor: T+60d in 13h
Latest observation: T+56 -34.66% FF3 residual α
Entry = T+0 close
Aug 4, 2026
via day close
T+1d
-3.50%
call -3.50% · α -3.34%
$1.38
settled 3mo ago
T+5d
+0.70%
call +0.70% · α +0.35%
$1.44
settled 3mo ago
T+20d
+18.88%
call +18.88% · α +19.48%
$1.70
settled 8w ago
T+60d
Pending
in 13h

Price Chart

Loading chart...

Executive Summary

Hyperscale Data, Inc. (HSD) filed a Form 3 initial statement of beneficial ownership for Alzamend Neuro (ALZN), disclosing indirect ownership of multiple tranches of common stock purchase warrants exercisable into ALZN common shares. The filing is a routine Section 16 compliance action triggered by HSD's director-by-deputization status via its subsidiary chain (Ault Lending → Ault Capital Group → HSD) and Milton C. Ault III's board seat at ALZN. No new economic exposure or change in position is signaled — this is purely a reporting formality to register HSD and its intermediate entities as direct Section 16 filers.

Key Facts

  • Hyperscale Data, Inc. filed a Form 3 initial beneficial ownership statement for Alzamend Neuro (ALZN).
  • HSD indirectly holds warrants exercisable into ALZN common stock through its wholly-owned subsidiary Ault Lending, LLC.
  • Warrant tranches cover exercise periods from 2021–2029 with varying exercise prices ($108.00, $4,050.00).
  • Milton C. Ault III, HSD's Executive Chairman, serves on ALZN's board, creating director-by-deputization status for HSD.
  • This filing is a routine Section 16 compliance action — no new investment or change in position.

Financial Impact

No financial impact — filing is a procedural ownership disclosure with no transaction or change in position.

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001214659-26-009595
Document: 0001214659-26-009595-index.html0001214659-26-009595
Document: 0001214659-26-009595.txt0001214659-26-009595
3 reports for ALZN
Performance horizon
Filters
Rows
Reports for ALZN — sortable, filterable
TypeNow
Sep 29, 2026
28d ago
8-K
NEUTRAL ★ 3/10
$1.82 $1.13▼ −37.91%▼ −38.63%$1.13 (−37.91%)
Aug 4, 2026
11w ago
3
NEUTRAL ★ 2/10
$1.43 $1.70▲ +18.88%▲ +19.48%$1.13 (−20.98%)
Feb 26, 2026
34w ago
DEFA14A
NEUTRAL ★ 4/10
$2.01 $1.05▼ −47.76%▼ −40.20%$1.13 (−43.78%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026